Pfizer strikes Innovent deal worth up to $10.5B for a dozen cancer programs

On the eve of this year’s ASCO annual meeting, Pfizer said it is teaming up with China’s Innovent Biologics to advance a portfolio of 12 early-stage antibody-drug conjugates and multi-specific antibodies in a deal that could be worth up to $10.5 billion.

Raccontata damorningstar.combiopharmadive.comthehindubusinessline.comcnbc.comscmp.combenzinga.compharmaceutical-technology.comstartmag.itendpoints.newsqz.comfiercepharma.com